Quince Therapeutics, Inc.
QNCX
$1.63
$0.021.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 42.12% | -34.81% | -40.07% | -2.64% | -467.52% |
| Total Depreciation and Amortization | -20.45% | -20.00% | -94.74% | -- | 4,300.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.23% | -6.04% | 32.40% | -378.10% | 2,276.66% |
| Change in Net Operating Assets | -31.65% | 354.78% | 658.00% | -92.41% | -807.46% |
| Cash from Operations | -30.62% | -14.94% | -24.25% | -50.68% | -128.35% |
| Capital Expenditure | -223.08% | -279.49% | -454.17% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 224.82% | 23.38% | 46.08% | 96.73% | 75.70% |
| Cash from Investing | 221.31% | 22.26% | 101.61% | 95.46% | 75.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 41,077.14% | -54.21% | -100.00% | -100.00% | 34.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 41,077.14% | -54.21% | -100.00% | -50,100.00% | 34.62% |
| Foreign Exchange rate Adjustments | 107.88% | -43.55% | 189.16% | -138.71% | -501.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 165.04% | 46.94% | 501.93% | -412.28% | 42.14% |